DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Alex Thompson - 4 Biden - 2 Axios - 1 Alex Thompson Alex Thompson - 1 Robert Hur - 1 Nikki Haley - 1 Haley - 1 It's - 1
Top related locs:
New Hampshire Indianapolis Bengaluru New Jersey United States
Top related orgs:
New - 2 Trump - 2 New Hampshire GOP - 1 New Hampshire Republican - 1 Dice Therapeutics - 1 U.S . Federal Trade Commission - 1 Pharmaceuticals - 1 Thomson - 1

Search resuls for: "Alex Thompson"


8 mentions found


☆ No Democrat I talked to felt Biden did himself any favors last night, says Axios' Alex Thompson
  + stars: | 2024-02-09 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNo Democrat I talked to felt Biden did himself any favors last night, says Axios' Alex ThompsonAlex Thompson, Axios national political correspondent, joins 'Squawk Box' to discuss Biden's press conference responding to a report from special counsel Robert Hur, questions surrounding his memory, potential impact on the 2024 race, and more.
Persons: Biden, Axios, Alex Thompson Alex Thompson, Robert Hur
☆ New Hampshire GOP primary: What's at stake for Nikki Haley today
  + stars: | 2024-01-23 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNew Hampshire GOP primary: What's at stake for Nikki Haley todayAlex Thompson, Axios national political correspondent, joins 'Squawk Box' to preview today's New Hampshire Republican primary, what a Trump win tonight would mean for the Haley campaign, the state of the 2024 general election, and more.
Persons: Nikki Haley, Alex Thompson, Haley Organizations: New, New Hampshire GOP, New Hampshire Republican, Trump Locations: New Hampshire
☆ Stifel says this under-the-radar biotech stock can still rally more than 50% from here
  + stars: | 2023-11-02 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +1 min
It's not too late for investors to ride along with MoonLake Immunotherapeutics despite the Swiss biotech having more than quadrupled in price this year, according to Stifel. Shares of MoonLake have soared 354% in 2023, but Stifel believes more gains lay ahead. MLTX YTD mountain MLTX YTD chart Analyst Alex Thompson believes MoonLake's sonelokimab drug, which targets diseases in dermatology and rheumatology, could eventually achieve $4.2 billion in U.S. revenue. The next trial readout for the drug is in psoriatic arthritis, with data expected in early November. "We view recent acquisitions in the TYK2 and TL1A space ($4-11B) as supportive of Strategics' interest/willingness to pay premiums in these markets," Stifel noted.
Persons: It's, MoonLake Immunotherapeutics, Stifel, Alex Thompson, we've, Thompson, MoonLake, — CNBC's Michael Bloom
☆ Eli Lilly to buy immunology drug developer Dice for $2.4 billion
  + stars: | 2023-06-20 | by ( ) www.reuters.com   time to read: +2 min
June 20 (Reuters) - Eli Lilly and Co (LLY.N) agreed to buy Dice Therapeutics Inc (DICE.O) for about $2.4 billion in cash on Tuesday, bolstering its immune disease-related portfolio with a largely oral drug developer. Dice's lead drug DC-806, which is currently in a mid-stage trial, is an immunology drug for a skin condition called psoriasis and other diseases. Indianapolis-headquartered Lilly is focusing on immunology to drive future growth, along with a widely expected approval of obesity drug candidate tirzepatide. Lilly has offered Dice $48 per share in cash, a premium of about 42% to the stock's last close. Lilly's Taltz garnered $2.48 billion in 2022 while its other immunology drug Olumiant generated $830.5 million in sales.
Persons: Eli Lilly, Taltz, Lilly, tirzepatide, Lilly's Taltz, Alex Thompson, Leroy Leo, Khushi, Sriraj Organizations: Dice Therapeutics, U.S . Federal Trade Commission, Pharmaceuticals, Thomson Locations: Indianapolis, Bengaluru
☆ Chris Christie just made the GOP primary pettier with his deep beef against the Kushners
  + stars: | 2023-06-07 | by ( Sarah Gray | ) www.businessinsider.com   time to read: +5 min
The Chris Christie beef with the Kushner family runs deep. Chris Christie and the Kushner family was once again center stage on Tuesday in what is shaping up to be a pretty petty presidential primary season. "Jared Kushner and Ivanka Kushner walk out of the White House and months later get $2 billion from the Saudis. But his beef with the Kushner family goes back much further than this campaign cycle. Jared Kushner went on to work for four years at the White House as a senior adviser to his father-in-law.
Persons: Chris Christie, Kushner, Christie, Jared Kushner, Alex Thompson, —, Donald Trump —, Trump, Joe Biden, Trump —, Trump's, Ivanka Trump, Ivanka Kushner, Saudi Crown Prince Mohammed bin Salman, Jared, Jared's, Charles Kushner, savaging Sen, Marco Rubio, Mike Pence, PBS's Margaret Hoover, Mr, Charles Kushner's, Margaret —, Biden Organizations: Service, New, New Jersey Gov, Trump, White, Saudi Crown, Public Investment Fund, Kushner's Affinity Partners, New York Times, Federal, Commission, GOP Locations: New Hampshire, New Jersey, United States
☆ Fox News joked about DeSantis' glitchy campaign launch to his face
  + stars: | 2023-05-25 | by ( Rebecca Cohen | ) www.businessinsider.com   time to read: +2 min
Ron DeSantis' presidential campaign announcement didn't go as planned — and Fox News joked about it moments later. DeSantis joined Trey Gowdy on Fox News for an interview after the glitchy announcement. "I can't promise you that I won't crash, but Fox News will not crash in this interview," Gowdy told the Florida governor. Ron DeSantis appeared on Fox News Wednesday night — only to be teased by host Trey Gowdy. While DeSantis was attempting to speak on Twitter, FoxNews.com included a banner with a "programming note" on their site that read: "Want to actually see and hear Ron DeSantis?
☆ Progress made in White House debt limit meeting as talks continue
  + stars: | 2023-05-17 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailProgress made in White House debt limit meeting as talks continueAlex Thompson, Axios National Political Correspondent, joins 'Squawk Box' to discuss the latest in debt ceiling negotiations, following a second meeting Tuesday between President Biden and top congressional leaders.
☆ Aclaris shares tank as skin disorder drug fails mid-stage study
  + stars: | 2023-03-06 | by ( ) www.reuters.com   time to read: +1 min
Companies Aclaris Therapeutics Inc FollowMarch 6 (Reuters) - Aclaris Therapeutics Inc (ACRS.O) said on Monday its experimental drug failed to meet the main goal of a mid-stage study to treat a painful skin disorder, sending its shares tumbling more than 36% in premarket trading. The drug, zunsemetinib, did not meet the main goal of reducing abscesses in patients with moderate to severe hidradenitis suppurativa (HS) at week 12, compared with a placebo. HS is a chronic inflammatory skin condition that causes abscesses and scarring on the skin. The study also failed to meet its secondary goals, which included percentage of patients who achieved at least a 50% reduction in number of inflammatory lesions, Aclaris said. The drug is being tested to treat other inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis, far bigger markets than HS.
0 next >>
Total: 8